Nothing Special   »   [go: up one dir, main page]

AR060618A1 - Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo - Google Patents

Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo

Info

Publication number
AR060618A1
AR060618A1 ARP070101715A ARP070101715A AR060618A1 AR 060618 A1 AR060618 A1 AR 060618A1 AR P070101715 A ARP070101715 A AR P070101715A AR P070101715 A ARP070101715 A AR P070101715A AR 060618 A1 AR060618 A1 AR 060618A1
Authority
AR
Argentina
Prior art keywords
halogens
optionally substituted
alkyl
halogen
independently
Prior art date
Application number
ARP070101715A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR060618A1 publication Critical patent/AR060618A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuesto de ciclohexilpirazol-lactama, de la formula (1) donde: R1 es -H, -halogeno, -O-CH3 (opcionalmente substituido con uno a tres halogenos), o -CH3 (opcionalmente substituido con uno a tres halogenos); R2 es -H, -halogeno, -O-CH3 (opcionalmente substituido con uno a tres halogenos), o -CH3 (opcionalmente substituido con uno a tres halogenos); R3 es -H o -halogeno; R4 es: -OH, -halogeno, -ciano, -alquilo C1-4 (opcionalmente substituido con uno a tres halogenos), -alcoxi C1-6 (opcionalmente substituido con uno a tres halogenos), -SCF3, -C(O)Oalquilo C1-4, -OCH2-C(O)NH2, -cicloalquilo C3-8, -O-fenil-C(O)O-alquilo C1-4, -CH2-fenil, -NHSO2-alquilo C1-4, -NHSO2-fenil(R21)(R21), -alquilo C1-4-C(O)N(R10)(R11), - C(O)N(R10)(R11), formulas (2) en donde la línea punteada representa el punto de enlace en la posicion R4 en la formula 1; en donde m es 1, 2, o 3; en donde n es 0, 1, o 2, y en donde cuando n es 0, luego ô(CH2) nö es un enlace; R5 es -H, -halogeno, - OH, -CN, -alquilo C1-4 (opcionalmente substituido con 1 a 3 halogenos), -C(O)OH, -C(O)O-alquilo C1-4, -C(O)-alquilo C1-4, -O-alquilo C1-4 (opcionalmente substituido con 1 a 3 halogenos), -SO2-alquilo C1-4, -N(R8)(R8), -fenil(R21)(R21), -C(O)-NH- cicloalquilo C3-6, formulas (3) en donde la línea punteada representa el punto de enlace en la posicion indicada por R5; en donde m es 1 2, o 3; en donde n es 0, 1, o 2, y en donde cuando n es 0, luego ô(CH2) nö es un enlace; R6 es -H, -halogeno, - CN, -alquilo C1-4 (opcionalmente substituido con 1 a 3 halogenos), -O-alquilo C1-4 (opcionalmente substituido con 1 a 3 halogenos), o formula (4); R7 es -H, -halogeno, o -alquilo C1-4 (opcionalmente substituido con 1 a 3 halogenos); R8 es independientemente cada que se presenta -H, -alquilo C1-6 (opcionalmente substituido con 1 a 3 halogenos), -C(O)alquilo C1-6 (opcionalmente substituido con 1 a 3 halogenos), -C(O)-cicloalquilo C3-8, -S(O2)- cicloalquilo C3-8 o -S(O2)-alquilo C1-3 (opcionalmente substituido con 1 a 3 halogenos); R9 es -H o -halogeno; R10 y R11 son cada uno independientemente -H o -alquilo C1-4, o R10 y R11 tomados juntos con el nitrogeno al cual se enlazan forman piperidinilo, piperazinilo, o pirrolidinilo; R20 es independientemente cada que se presenta -H, o -alquilo C1-3 (opcionalmente substituido con 1 a 3 halogenos); R21 es independientemente cada que se presenta -H, -halogeno, o -alquilo C1-3 (opcionalmente substituido con 1 a 3 halogenos); R22 es independientemente cada que se presenta -H o - alquilo C1-6 (opcionalmente substituido con 1 a 3 halogenos); y R23 es independientemente cada que se presenta -H, -alquilo C1-4, o -C(O)O-alquilo C1-4; o un estereoisomero del mismo; o una sal farmacéuticamente aceptable del mismo. Composicion farmacéutica que lo comprende. Su uso para preparar un medicamento util para tratar síndromes metabolicos, diabetes tipo 2 o arterosclerosis y otras condiciones asociadas con la actividad 11 beta- HSD de tipo 1. Intermediarios para preparar el compuesto (3R)-3-[3,5-Dicloro-4'-fluoro[1,1'-bifenil]-4-iI)metil]-1-[(5S)4,5,6,7-tetrahidro-1H-indazol-5-iI]-2-pirrolidinona.
ARP070101715A 2006-04-21 2007-04-20 Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo AR060618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74532006P 2006-04-21 2006-04-21

Publications (1)

Publication Number Publication Date
AR060618A1 true AR060618A1 (es) 2008-07-02

Family

ID=38595048

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101715A AR060618A1 (es) 2006-04-21 2007-04-20 Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo

Country Status (30)

Country Link
US (1) US7981918B2 (es)
EP (1) EP2029579B1 (es)
JP (1) JP5161869B2 (es)
KR (1) KR101055576B1 (es)
CN (1) CN101426783B (es)
AR (1) AR060618A1 (es)
AU (1) AU2007240550B2 (es)
BR (1) BRPI0710229A2 (es)
CA (1) CA2647677C (es)
CO (1) CO6140026A2 (es)
CR (1) CR10400A (es)
DO (1) DOP2007000078A (es)
EA (1) EA015675B1 (es)
EC (1) ECSP088839A (es)
ES (1) ES2533263T3 (es)
HK (1) HK1126493A1 (es)
IL (1) IL194835A (es)
JO (1) JO3042B1 (es)
MA (1) MA30476B1 (es)
MX (1) MX2008013484A (es)
MY (1) MY148128A (es)
NO (1) NO20084403L (es)
NZ (1) NZ571175A (es)
PE (1) PE20080362A1 (es)
SV (1) SV2008003070A (es)
TN (1) TNSN08405A1 (es)
TW (1) TWI347321B (es)
UA (1) UA95798C2 (es)
WO (1) WO2007124254A2 (es)
ZA (1) ZA200808686B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007124329A1 (en) 2006-04-21 2007-11-01 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8088776B2 (en) 2006-04-21 2012-01-03 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8153807B2 (en) 2006-04-24 2012-04-10 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127704A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127693A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PL2021337T3 (pl) 2006-04-25 2010-06-30 Lilly Co Eli Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
MX2008013656A (es) * 2006-04-25 2008-11-10 Lilly Co Eli Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa.
DE602007007211D1 (de) 2006-04-25 2010-07-29 Lilly Co Eli Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
SI2049513T1 (sl) 2006-04-28 2012-04-30 Lilly Co Eli Piperidinil substituirani pirolidinoni kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
US8835426B2 (en) 2007-02-26 2014-09-16 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR069207A1 (es) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
CA2708303A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceuticals, Inc. Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
WO2009134400A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010011314A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
EP2324017B1 (en) 2008-07-25 2014-12-31 Boehringer Ingelheim International GmbH INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1
EP2323994A1 (en) 2008-07-25 2011-05-25 Boehringer Ingelheim International GmbH Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
WO2010091067A2 (en) * 2009-02-04 2010-08-12 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8552212B2 (en) 2009-11-05 2013-10-08 Boehringer Ingelheim International Gmbh Chiral phosphorus ligands
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP2013531636A (ja) 2010-05-26 2013-08-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 2−オキソ−1,2−ジヒドロピリジン−4−イルボロン酸誘導体
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
BR112013010021A2 (pt) 2010-11-02 2019-09-24 Boehringer Ingelheim Int combinações farmacêuticas para o tratamento de distúrbios metabólicos.
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI545113B (zh) 2011-10-18 2016-08-11 安斯泰來製藥股份有限公司 二環式雜環化合物
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
US10858347B2 (en) 2015-12-31 2020-12-08 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
AU2022224918B2 (en) 2021-02-25 2023-04-13 Aptabio Therapeutics Inc. Novel pyrazole derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
CN101001836B (zh) * 2004-05-07 2010-12-22 詹森药业有限公司 作为11-β羟基类固醇脱氢酶抑制剂的吡咯烷-2-酮和哌啶-2-酮衍生物
KR101193464B1 (ko) 2004-05-07 2012-10-24 얀센 파마슈티카 엔.브이. 11-베타 하이드록시스테로이드 탈수소효소 저해제로서의아다만틸 피롤리딘-2-온 유도체
EP1802623A1 (en) 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
ES2318577T3 (es) 2004-10-29 2009-05-01 Eli Lilly And Company Derivados de cicloalquil lactama como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1'.
NZ554906A (en) 2004-11-10 2011-01-28 Incyte Corp Lactam compounds and their use as pharmaceuticals
US20080214621A1 (en) 2004-12-20 2008-09-04 Thomas Daniel Aicher Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1
US7834194B2 (en) 2004-12-21 2010-11-16 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US20090264650A1 (en) 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
ES2322727B1 (es) 2005-07-28 2010-04-22 Universidad Del Pais Vasco Metodo para cuantificar la union receptor acoplado a proteina g (gpcr)-proteina g mediante el empleo de un array de membranas celulares.
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007124329A1 (en) 2006-04-21 2007-11-01 Eli Lilly And Company Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8088776B2 (en) 2006-04-21 2012-01-03 Eli Lilly And Company Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127693A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8153807B2 (en) 2006-04-24 2012-04-10 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2007127704A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
MX2008013656A (es) 2006-04-25 2008-11-10 Lilly Co Eli Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa.
DE602007007211D1 (de) 2006-04-25 2010-07-29 Lilly Co Eli Inhibitoren von11-beta-hydroxysteroiddehydrogenase 1
PL2021337T3 (pl) 2006-04-25 2010-06-30 Lilly Co Eli Inhibitory dehydrogenazy 11-beta-hydroksysteroidowej typu 1
SI2049513T1 (sl) 2006-04-28 2012-04-30 Lilly Co Eli Piperidinil substituirani pirolidinoni kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.

Also Published As

Publication number Publication date
MA30476B1 (fr) 2009-06-01
EA200870460A1 (ru) 2009-04-28
JP2009534398A (ja) 2009-09-24
TW200811141A (en) 2008-03-01
ECSP088839A (es) 2008-11-27
NZ571175A (en) 2011-10-28
EA015675B1 (ru) 2011-10-31
US7981918B2 (en) 2011-07-19
UA95798C2 (ru) 2011-09-12
CN101426783A (zh) 2009-05-06
CA2647677A1 (en) 2007-11-01
US20090111800A1 (en) 2009-04-30
AU2007240550A1 (en) 2007-11-01
SV2008003070A (es) 2010-01-18
CO6140026A2 (es) 2010-03-19
KR20080109867A (ko) 2008-12-17
JP5161869B2 (ja) 2013-03-13
CN101426783B (zh) 2013-10-30
DOP2007000078A (es) 2007-11-15
PE20080362A1 (es) 2008-04-25
WO2007124254A2 (en) 2007-11-01
BRPI0710229A2 (pt) 2011-08-02
MX2008013484A (es) 2008-10-30
IL194835A (en) 2015-04-30
AU2007240550B2 (en) 2012-02-23
TNSN08405A1 (en) 2010-04-14
HK1126493A1 (en) 2009-09-04
EP2029579A2 (en) 2009-03-04
IL194835A0 (en) 2009-08-03
EP2029579B1 (en) 2014-12-31
ZA200808686B (en) 2009-12-30
TWI347321B (en) 2011-08-21
KR101055576B1 (ko) 2011-08-08
CA2647677C (en) 2014-03-18
ES2533263T3 (es) 2015-04-08
CR10400A (es) 2009-01-14
MY148128A (en) 2013-02-28
JO3042B1 (ar) 2016-09-05
NO20084403L (no) 2008-11-14
WO2007124254A3 (en) 2007-12-27

Similar Documents

Publication Publication Date Title
AR060618A1 (es) Compuesto de ciclohexilpirazol-lactama composicion farmaceutica que comprende dicho compuesto su uso para la preparacion de un medicamento e intermediarios para prepararlo
AR068054A1 (es) Compuestos de pirrolopirimidina
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
PE20070343A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR082985A1 (es) INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
ECSP088773A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR074359A1 (es) Compuestos heterociclicos sustituidos como moduladores de canales ionicos
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR058065A1 (es) Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas.
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
AR067105A1 (es) Moleculas pequenas que contienen boro
AR048939A1 (es) Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios.
AR061134A1 (es) Derivados de tioxantina
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR082994A1 (es) Derivados de pirazina como bloqueadores del canal epitelial de sodio
AR073922A1 (es) 2- oxoquinoxalinas como bloqueadores de los canales de sodio tardios
CR10383A (es) Derivados triazolopirazina.
HRP20100397T1 (hr) INHIBITORI 11-ß-HIDROKSISTEROID-DEHIDROGENAZE 1
AR067412A1 (es) Moduladores de propiedades farmaceuticas de productos terapeuticos
ECSP055815A (es) Composición para el tratamiento de la infección por virus flaviviridae
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee